Bain Capital Moves to Acquire Majority Stake in Echo Marketing 
Tesla Poised for Breakout Year in 2026 as New Products and EV Market Reset Drive Growth 
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026 
Samsung Electronics Hits Record High as AI Momentum Fuels Investor Optimism 
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Short Interest Rises in Trump Media Stock After $6 Billion Merger Announcement 
Trump Blocks HieFo’s Emcore Chip Assets Deal Over National Security Concerns 
Grok AI Controversy on X Sparks Global Outrage Over Nonconsensual Images 
L3Harris Nears $500M Deal to Sell Majority Stake in Space Propulsion Portfolio to AE Industrial 
Reddit Emerges as a Major Winner in the Shift to AI-Powered Search 
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 
CAMBRIDGE, Mass., Oct. 23, 2017 -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) based on its proprietary Dolaflexin® platform, today announced that it will report preclinical data on its second product candidate, XMT-1536, in a poster to be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutic, held October 26-30 in Philadelphia. Presentation details are as follows:
| Title: | Relationship of NaPi2b expression and efficacy of XMT-1536, a NaPi2b targeting antibody-drug conjugate (ADC), in an unselected panel of human primary ovarian mouse xenograft models | ||
| Session: | Poster Session B, Therapeutic Agents: Biological | ||
| Presenter: | Rebecca Mosher, M.D., Executive Director, Translational Medicine | ||
| Date and Time: | Sunday, October 29, 2017, 12:30 p.m. - 4:00 p.m. ET | ||
| Poster/Abstract: | 119/B119 |
About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop highly targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersana’s lead product candidate, XMT-1522, is in Phase I clinical trials in patients with advanced tumors expressing HER2, including breast cancer, non-small-cell-lung-cancer (NSCLC) and gastric cancer patients. The Company expects that its second product candidate, XMT-1536, will enter clinical trials in early 2018. In addition, multiple partners are using Mersana’s leading platform to advance their ADC pipelines.
Media Contact
Paul Kidwell
[email protected]
617-680-1088
Investors Contact
Stern Investor Relations, Inc.
Christina Tartaglia
[email protected]
(212) 362-1200
